PHOENIXP PHARMACEUTICALS, INC. TOP HOME PAGE
Top » Catalog My Account | CONTACT US |



 Peptides



 Labeled Peptides 



 Peptide Libraries



 Antibodies 



 Kits 



 Biomarker Array 



 Organic Compounds



 Stem Cell Reagents



 Peptide Level Determination



 Custom synthesis & GMP



 Catalog Request



 Sample Preparation



 FAQs


QRFP-43
a new obesity peptide

Central administration of the RFamide peptides, QRFP-26 and QRFP-43, increases high fat food intake in rats

Pyrogultamylated arginine-phenylalanineamide peptide (QRFP) is strongly conserved across species and is a member of the family of RFamide-related peptides, with the motif Arg-Phe-NH(2) at the C-terminal end. The precursor peptide for QRFP generates a 26-amino acid peptide (QRFP-26) and a 43-amino acid peptide (QRFP-43), both of which bind to the G protein-coupled receptor, GPR103. Recently, QRFP has been characterized in rats, mice and humans and has been reported to have orexigenic properties. In rodents, prepro-QRFP mRNA is expressed in localized regions of the mediobasal hypothalamus, a region implicated in feeding behavior. Increased intake of a high fat diet contributes to increased weight gain and obesity. Therefore, the current experiments investigated the effects of QRFP administration in rats and the effects of a high fat diet on prepro-QRFP mRNA and GPR103 receptor mRNA levels. Intracerebroventricular administration of QRFP-26 (3.0nM, 5.0nM) and QRFP-43 (1.0nM, 3.0nM) dose-dependently increased 1h, 2h, and 4h cumulative intake of high fat (55% fat), but not low fat (10% fat) diet. In Experiment 2, hypothalamic prepro-QRFP mRNA levels and GPR103 receptor mRNA levels were measured in rats fed a high fat or a low fat diet for 21 days. Prepro-QRFP mRNA was significantly increased in the ventromedial nucleus/arcuate nucleus of the hypothalamus of rats fed a high fat diet compared to those fed a low fat diet, while GPR103 mRNA levels were unchanged. These findings suggest that QRFP is a regulator of dietary fat intake and is influenced by the intake of a high fat diet.
Primeaux SD, et al. Peptides. 2008 Nov;29(11):1994-2000. Epub 2008 Aug 13.
 
RF amide peptide QRFP43 causes obesity with hyperphagia and reduced thermogenesis in mice
QRFP, an RF amide peptide, was recently identified as an endogenous ligand of an orphan G protein-coupled receptor, GPR103. Recent investigation revealed that acute intracerebroventricular (ICV) administration of QRFP26/P518/26RFa, a constitutive part of QRFP43 (43-amino acid-residue form of QRFP), increases appetite in mice, but its role in long-term energy homeostasis remains unknown. In the present study, we examined the effects of chronic administration of QRFP43 on feeding behavior, body weight regulation and energy expenditure in mice. ICV infusion of QRFP43 for 13 days resulted in a significant increase in body weight and fat mass with hyperphagia. Weight gain and hyperphagia were more evident when mice were fed a moderately high-fat diet. Pair-feeding of QRFP43-infused mice did not increase body weight, but significantly increased fat mass and plasma concentrations of insulin, leptin and cholesterol when compared with controls. Moreover, significant decreases in rectal temperature and expression of brown adipose tissue uncoupling protein-1 mRNA were observed in QRFP43-infused ad libitum- and pair-fed mice. The present results suggest that QRFP plays an important role in energy homeostasis by regulating appetite and energy expenditure.
Moriya R, et al. Endocrinology. 2006 Mar 16; [Epub ahead of print]
   
Antibody for QRFP western blot and immunohistochemistry Antibody for QRFP receptor AQ27 western blot and Immunohistochemistry
QRFP
 

Data Sheet / Protocol

QRFP-43
QRFP-43
 
Moriya R, et al. Endocrinology. 2006 Mar 16; [Epub ahead of print]
Body composition, tissue weights and hepatic triglyceride (TG) contents of mice infused with QRFP43
QRFP
Data are means ± SE of 6-11 mice. #, P < 0.05; *, P < 0.01 vs. respective vehicle-treated group (Student’s t-test or ANOVA
followed by Dunnett’s test). n.t.: not tested.Moriya R, et al. Endocrinology. 2006 Mar 16; [Epub ahead of print]
QRFP
Data are means ± SE of 6-11 mice. FFA, free fatty acid; TG, triglyceride; CHL, Cholesterol #, P < 0.05; *, P < 0.01 vs. respective vehicle-treated group (Student’s t-test or ANOVA followed by Dunnett’s test).Moriya R, et al. Endocrinology. 2006 Mar 16; [Epub ahead of print]
QRFP
Data are means ± SE of 14-15 mice. FFA, free fatty acid; TG, triglyceride; CHL, Cholesterol #, P < 0.05; *, P < 0.01 vs. vehicle-treated group (ANOVA followed by Dunnett’s test). Moriya R, et al. Endocrinology. 2006 Mar 16; [Epub ahead of print]
Effects of ICV-injected QRFP 43 on food intake in mice Data are means ± SE of 11-13 mice. *, P < 0.01 vs. vehicle-treated group. Moriya R, et al. Endocrinology. 2006 Mar 16; [Epub ahead of print]
Body weight changes (A), daily food intake (B), cumulative food intake (C) and fat content (D) of mice chronically infused with vehicle or QRFP43 (30 μg/day) under regular-diet conditions. Data are means ± SE of 6-7 mice. #, P < 0.05 vs. vehicle-treated group (Student’s t-test). Moriya R, et al. Endocrinology. 2006 Mar 16; [Epub ahead of print]
Body weight changes (A), daily food intake (B), cumulative food intake (C) and fat content (D) of mice chronically infused with vehicle or QRFP43 (3, 10, 30 μg/day) under MHF-diet conditions. Data are means ± SE of 9-11 mice. #, P < 0.05; *, P < 0.01 vs. respective vehicle-treated group (ANOVA followed by Dunnett’s test). Moriya R, et al. Endocrinology. 2006 Mar 16; [Epub ahead of print]
Body weight changes (A), cumulative food intake (B) and fat content (C) of mice chronically infused with vehicle, QRFP43/ad lib-fed (10 μg/day) or QRFP43/pair-fed (10 μg/day) under MHF-diet conditions. Data are means ± SE of 14-15 mice. *, P < 0.01 vs. vehicle-treated group (ANOVA followed by Dunnett’s test). Moriya R, et al. Endocrinology. 2006 Mar 16; [Epub ahead of print]

Rectal temperature (A) and BAT UCP1 mRNA expression (B) of mice infused with vehicle, QRFP43/ad lib-fed (10 μg/day) or QRFP43/pair-fed (10 μg/day).
Data are means ± SE of 14-15 mice. #, P < 0.05; *, P < 0.01 vs. vehicle-treated group (ANOVA followed by Dunnett’s test). Moriya R, et al. Endocrinology. 2006 Mar 16; [Epub ahead of print]

   

 

Identification and characterization of a novel RF-amide peptide ligand for orphan G-protein coupled receptor SP9155
Orphan G-protein coupled receptors are a large class of receptors whose cognate ligands are unknown. SP9155 (also referred to as AQ27 and GPR103) is an orphan G-protein coupled receptor originally cloned from a human brain cDNA library. SP9155 was found to be predominantly expressed in brain, heart, kidney, retina and testis. Phylogenetic analysis shows that SP9155 shares high homology with Orexin, NPFF and CCK receptors, but identification of the endogenous ligand for SP9155 has not been reported. In this study, we have used a novel method to predict peptides from genome databases. From these predicted peptides, a novel RF-amide peptide, P52 was shown to selectively activate SP9155-transfected cells. We subsequently cloned the precursor gene of the P52 ligand and characterized the activity of other possible peptides encoded by the precursor. This revealed an extended peptide, P518, which exhibited high affinity for SP9155 (EC50 = 7 nM). mRNA expression analysis revealed that the peptide P518 precursor gene is predominantly expressed in various brain regions, coronary arteries, thyroid and parathyroid glands, large intestine, colon, bladder, testes and prostate. These results indicate the existence of a novel RF-amide neuroendocrine peptide system, and suggest that SP9155 is likely the relevant G-protein coupled receptor for this peptide.
Jiang Y, et al., J Biol Chem 2003 Apr 24; [epub ahead of print].

A new peptidic ligand and its receptor regulating adrenal function in rats
SUMMARY We searched for peptidic ligands for orphan G protein-coupled receptors utilizing a human genome database and identified a new gene encoding a preproprotein that could generate a peptide. This peptide consisted of 43 amino acid residues that starting from N-terminal pyroglutamic acid and ending at C-terminal arginine-phenylalanin-amide. We therefore named it QRFP after pyroglutamylated arginine-phenylalanine-amide peptide. We subsequently searched for its receptor and found that Chinese hamster ovary cells expressing an orphan G protein-coupled receptor, AQ27, specifically responded to QRFP. We analyzed tissue distributions of QRFP and its receptor mRNAs in rats utilizing quantitative reverse transcription-polymerase chain reaction and in situ hybridization. QRFP mRNA was highly expressed in the hypothalamus and its receptor mRNA in the adrenal gland. The intravenous administration of QRFP caused the release of aldosterone, suggesting that QRFP and its receptor have a regulatory function in the rat adrenal gland.
Fukusumi S, et al. J Biol Chem. 2003 Sep 5 [Epub ahead of print].

P518/Hypothetical Protein-Related Products

 

RFRP;P518;NPAF;metastin

%048-78%;%048-76%;%048-75%;%048-74%;%048-72%;%049-61%;%049-60%;%001-81%;%049-59%;%048-77%


Search in :
Enter keyword
or choose a LETTER
A B C D E F G H I J K L M N
O P Q R S T U V W X Y Z
0 items



Copyright © 2010 PHOENIX PHARMACEUTICALS, INC.

Select your company location: